Chargement en cours...
Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
OBJECTIVE: Patients with Lennox‐Gastaut syndrome (LGS) who completed 1 of 2 randomized, double‐blind, placebo‐controlled trials of add‐on cannabidiol (CBD) (GWPCARE3, NCT02224560 or GWPCARE4, NCT02224690) were invited to enroll in an open‐label extension (OLE) study evaluating the long‐term safety a...
Enregistré dans:
| Publié dans: | Epilepsia |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6850399/ https://ncbi.nlm.nih.gov/pubmed/30740695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/epi.14670 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|